Last updated: September 17, 2026
Sucralfate is an established, off-patent gastrointestinal drug with limited active-ingredient exclusivity but meaningful formulation opportunities. Commercial differentiation is most likely in oral suspensions, unit-dose packaging, palatable pediatric or veterinary products, improved resuspendability, preservative systems, and supply-chain reliability. The main technical risks are aluminum-containing drug substance variability, excipient compatibility, sedimentation, microbial control, and reduced absorption of co-administered medicines.
What is sucralfate and how is it regulated?
Sucralfate is a basic aluminum complex of sucrose octasulfate. It is used primarily for duodenal ulcer treatment and maintenance therapy. The drug acts locally in the gastrointestinal tract by forming an adhesive barrier at ulcer sites rather than through systemic absorption.
The U.S. reference products are Carafate tablets and oral suspension. FDA approval records identify Carafate tablet NDA 018333 and oral suspension NDA 019462 as the principal reference-product applications.[1] Sucralfate products are generally approved through the abbreviated new drug application pathway when the generic product matches the reference product in active ingredient, dosage form, route, strength and relevant performance characteristics.
| Attribute |
Sucralfate |
| Active ingredient |
Sucralfate, aluminum sucrose sulfate |
| Main route |
Oral |
| Principal dosage forms |
Tablet and oral suspension |
| Primary therapeutic use |
Duodenal ulcer treatment and maintenance |
| Pharmacology |
Local gastrointestinal barrier |
| U.S. regulatory pathway |
NDA reference products; ANDA generic pathway |
| Current exclusivity profile |
No meaningful active-ingredient exclusivity expected |
| Primary commercial issue |
Formulation, packaging and supply execution |
Because sucralfate is minimally absorbed, formulation quality is judged heavily by local performance, dose uniformity, viscosity, dispersion, adhesion and administration convenience.
What excipients are used in sucralfate tablets and suspensions?
Sucralfate tablets typically require a compactible filler, binder, disintegrant, lubricant and processing aid. Oral suspensions require a vehicle, suspending system, wetting agent, viscosity modifier, sweetener, flavor, preservative where appropriate, and pH-control components.
Exact excipient selection must be confirmed against the reference-product labeling, FDA Inactive Ingredient Database and the target product specification. The following excipient classes are commercially relevant.
| Formulation function |
Candidate excipient classes |
Key development issue |
| Tablet filler |
Microcrystalline cellulose, starch-based fillers, dibasic calcium phosphate |
Compatibility with the aluminum complex and tablet hardness |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Granulation behavior and dissolution or dispersion |
| Disintegrant |
Sodium starch glycolate, crospovidone, croscarmellose sodium |
Rapid breakup without excessive powdering |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Over-lubrication can impair wetting |
| Glidant |
Colloidal silicon dioxide |
Flow improvement and dust control |
| Suspension vehicle |
Purified water, glycerin, sorbitol solution |
Palatability, density and microbial control |
| Suspending agent |
Xanthan gum, cellulose derivatives, structured polymer systems |
Sedimentation and redispersibility |
| Wetting agent |
Polysorbates or other low-level surfactants |
Uniform dispersion of poorly wettable material |
| Sweetener |
Sucrose, sorbitol, sucralose or other high-intensity sweeteners |
Patient acceptability and diabetes positioning |
| Preservative |
Benzoate, sorbate or other approved system |
pH dependence and preservative effectiveness |
| Flavor |
Fruit or neutral flavors |
Interaction with aluminum-containing drug substance |
| Buffer or pH modifier |
Citrate, phosphate or other appropriate systems |
Chemical stability and product performance |
The formulation target is not simply a high-viscosity suspension. Excessive viscosity can create inaccurate dosing, poor bottle emptying and difficult administration through oral syringes. A commercially viable product should remain homogeneous after moderate shaking, redisperse within a short period, pour consistently and maintain dose uniformity throughout the labeled in-use period.
What formulation challenges affect sucralfate product development?
How does aluminum-containing drug substance affect excipient selection?
Sucralfate is a complex inorganic-organic material rather than a conventional small-molecule powder. Its particle-size distribution, hydration state, bulk density and surface characteristics can vary between suppliers and manufacturing lots.
Those variables can alter:
- Suspension sedimentation rate
- Tablet compression behavior
- Wetting and dispersion
- Viscosity
- Dose uniformity
- Adhesion to manufacturing equipment
- Final product appearance
Drug-substance controls should include particle-size distribution, elemental composition, aluminum content, sulfate substitution or related structural attributes, loss on drying and microbial quality. The sponsor should establish supplier comparability before locking the excipient system.
What are the critical quality attributes for an oral suspension?
A sucralfate suspension should be evaluated for:
- Assay and content uniformity.
- Sedimentation volume.
- Redispersibility after storage.
- Viscosity at relevant shear rates.
- Delivered dose from the commercial container.
- Particle-size distribution.
- Microbial limits and preservative effectiveness.
- Chemical and physical stability.
- Container-closure compatibility.
- In-use stability after opening.
The suspension system should be designed around the intended administration method. A bottle for adult use can tolerate a different rheology from a pediatric product delivered through an oral syringe.
What excipients create the highest regulatory risk?
The greatest regulatory risk usually comes from excipients that materially alter product performance or raise safety questions in the intended population. Risk areas include:
- High sugar content in chronic-use products.
- Sorbitol or other polyols in patients with gastrointestinal sensitivity.
- Preservative exposure in pediatric or repeated-dose products.
- Surfactants that change wetting or local drug behavior.
- Novel polymers without established oral-use precedents.
- Excipients that bind aluminum or sulfate groups.
- Buffer systems that change the suspension’s chemical environment.
An ANDA sponsor generally has a stronger regulatory position when it uses well-characterized excipients with established oral precedent and can demonstrate pharmaceutical equivalence to the reference product.
What commercial opportunities exist for sucralfate formulations?
Is there an opportunity for a differentiated oral suspension?
Yes. Oral suspension is the strongest formulation opportunity because it creates more room for product-level differentiation than a conventional tablet.
Potential commercial advantages include:
- Faster redispersion.
- Reduced sedimentation.
- More accurate dosing after shaking.
- Better taste masking.
- Smaller bottle sizes.
- Unit-dose cups or sachets.
- Improved oral-syringe compatibility.
- Preservative-free packaging where technically feasible.
- Longer in-use stability.
- Lower shipping weight through concentrated presentations.
A suspension that performs consistently without prolonged shaking can reduce administration errors in outpatient and institutional settings. Claims must remain within the approved labeling unless supported through an approved regulatory pathway.
Are pediatric products commercially attractive?
Pediatric use can create a targeted opportunity, but it is technically demanding. The product must support accurate low-volume dosing, acceptable flavor, easy redispersion and a safe excipient profile.
A pediatric-focused presentation could use:
- Oral-syringe dosing.
- Graduated bottles.
- Lower-volume unit doses.
- Sugar-free flavor systems.
- Reduced viscosity for syringe delivery.
- Child-resistant but caregiver-friendly packaging.
The sponsor must avoid assuming that an adult suspension is suitable for children. Dose-volume accuracy, excipient exposure and palatability require separate development work.
Is veterinary sucralfate a viable segment?
Veterinary sucralfate is a practical adjacent market because animals often receive the drug as a crushed tablet or compounded suspension. A commercially manufactured veterinary suspension could compete on dosing consistency, shelf life and administration convenience.
Relevant product concepts include:
- Small-volume bottles for dogs and cats.
- Flavor systems compatible with veterinary administration.
- Oral syringes with species-specific dosing graduations.
- Unit-dose products for hospitals.
- Ready-to-use formulations that eliminate tablet crushing.
Veterinary products may follow a different regulatory pathway from human pharmaceuticals, depending on jurisdiction and claims. Intellectual-property protection is likely to center on formulation, packaging, manufacturing and brand assets rather than the sucralfate molecule.
What patents protect sucralfate products?
Sucralfate itself is an old active ingredient, and the principal commercial opportunity is not based on new-molecule patent exclusivity. The original product and core active-ingredient patents are generally expected to be expired or commercially irrelevant in the United States.
Current protection may arise from narrower rights covering:
- Specific suspension compositions.
- Preservative systems.
- Flavor-masked formulations.
- Unit-dose delivery systems.
- Manufacturing processes.
- Particle-size control.
- Combination products.
- Veterinary dosage forms.
- Trade dress and trademarks.
A patent search should distinguish between expired foundational patents and enforceable secondary patents. A formulation patent must be tested for claim scope, expiration, terminal disclaimers, prosecution history and potential invalidity. Patent presence alone does not establish a meaningful barrier to generic entry.
What is the Orange Book status of sucralfate?
The Orange Book remains the relevant U.S. reference for approved drug products, therapeutic-equivalence evaluations and listed patent or exclusivity information.[2] Sucralfate tablets and oral suspensions are established prescription products with generic competition.
For commercial diligence, the relevant questions are:
- Which Carafate reference products remain listed?
- Which generic manufacturers have active approvals?
- Are any product-specific patents listed?
- Are there therapeutic-equivalence ratings for the targeted dosage form?
- Are there discontinued or withdrawn presentations?
- Does the proposed product require an ANDA or a different application pathway?
Orange Book status can change as applications are withdrawn, discontinued or updated. A launch assessment should use the current FDA listing rather than historical approval data.
When does sucralfate lose exclusivity and what is the generic entry risk?
Sucralfate has already passed the principal exclusivity period associated with its original approvals. The commercial risk is therefore established generic competition rather than an approaching loss of exclusivity.
| Risk category |
Assessment |
| Active-ingredient patent risk |
Low |
| Original formulation exclusivity |
Expired or no longer commercially material |
| Paragraph IV risk |
Relevant only if an active listed patent applies to the target product |
| Tablet price erosion |
High because of mature generic competition |
| Suspension price erosion |
Moderate to high, depending on supplier count |
| Manufacturing barrier |
Moderate |
| Formulation differentiation potential |
Higher for suspensions than tablets |
| Biosimilar risk |
Not applicable |
| Supply disruption opportunity |
Potentially meaningful |
A new generic tablet would likely face direct price competition. A differentiated suspension can avoid some price pressure if it solves a specific administration or supply problem, but the market remains mature and relatively price-sensitive.
Which companies are competing in the sucralfate market?
The market includes the Carafate reference product, authorized generics and multiple generic manufacturers. Manufacturer participation varies by dosage form, market availability and wholesaler status.
The competitive landscape should be analyzed by:
- Active ANDA holder.
- Current commercial supplier.
- Tablet versus suspension availability.
- Bottle size and concentration.
- Wholesale acquisition cost.
- Back-order history.
- Manufacturing site.
- 503B or compounding alternatives.
- Hospital contract penetration.
Public FDA data can identify approved applicants, but approval does not prove continuous commercial supply. A product may remain approved while being unavailable or intermittently supplied.
How strong is the sucralfate patent estate?
The core patent estate is weak as a barrier to generic entry because sucralfate is an established, off-patent active ingredient. A new sponsor’s defensible position would depend on execution rather than broad molecule claims.
A stronger secondary patent position could arise from a formulation that has:
- Narrow but commercially relevant composition claims.
- Demonstrated stability or redispersibility advantages.
- A defined particle-size or rheology profile.
- Improved unit-dose delivery.
- A manufacturing process that reduces batch variability.
- A difficult-to-design-around excipient combination.
The strongest commercial protection may be regulatory and operational. Consistent supply, reliable suspension performance, approved labeling and pharmacy-channel access can matter more than a narrow patent that is difficult to enforce economically.
What manufacturing and intellectual-property barriers exist?
Manufacturing sucralfate requires control of both the active complex and the finished dosage form. Important barriers include:
- Consistent sourcing of qualified sucralfate.
- Control of hydration and particle-size variation.
- Prevention of powder segregation.
- Uniform incorporation into suspensions.
- Adequate mixing without excessive aeration.
- Preservative distribution.
- Bottle and closure compatibility.
- Cleaning validation for aluminum-containing residues.
- Long-term and in-use stability.
For tablets, tooling, compression force and lubricant levels can affect wetting and dispersion. For suspensions, high-shear processing can change particle behavior and entrain air. Process validation must show that the formulation remains within viscosity, assay and dose-delivery specifications across commercial-scale batches.
How does sucralfate compare with competing ulcer therapies?
Sucralfate competes with proton-pump inhibitors, H2-receptor antagonists and antacid products. Those alternatives often have stronger demand in acid-suppression indications, while sucralfate retains use where local mucosal protection, pregnancy-related prescribing considerations or clinical preference influence treatment.
| Product category |
Main advantage |
Commercial implication |
| Sucralfate |
Local barrier action and low systemic exposure |
Differentiation through suspension usability |
| Proton-pump inhibitors |
Strong acid suppression and broad use |
Larger competitive demand base |
| H2 antagonists |
Lower-cost acid suppression |
Price competition and substitution |
| Antacids |
Rapid symptomatic relief |
Over-the-counter access and convenience |
| Alginate products |
Physical barrier in reflux settings |
Formulation and consumer-brand competition |
Sucralfate’s competitive weakness is administration complexity. It is commonly taken on an empty stomach and can interfere with absorption of other medicines. A product that improves adherence without changing the approved dosing instructions could gain practical value.
What licensing and partnership opportunities exist?
Licensing opportunities are more likely to involve formulation and commercialization than active-ingredient rights. Potential deal structures include:
- Regional licensing of an approved generic suspension.
- Co-development of a pediatric presentation.
- Private-label supply for hospital systems.
- Contract manufacturing with dual sourcing.
- Veterinary formulation licensing.
- Unit-dose packaging partnerships.
- Authorized-generic commercialization.
- Acquisition of an abbreviated application with commercial supply rights.
The most attractive asset would combine an approved product, reliable manufacturing and a differentiated presentation. A patent-only asset without manufacturing capacity would have limited value in a mature generic market.
What launch scenarios are realistic for a new sucralfate product?
Standard generic tablet
This is the fastest route conceptually but carries the highest price pressure. Success depends on low manufacturing cost, reliable supply and pharmacy-channel scale.
Generic oral suspension
This offers better differentiation but requires more extensive development work. The sponsor must manage physical stability, microbial control, taste and dose delivery.
Premium convenience suspension
Unit-dose cups, sachets or premeasured oral syringes could target hospitals, long-term-care facilities and caregivers. The added packaging cost must be justified by reduced waste and administration error.
Veterinary product
This segment may offer better room for branding and formulation differentiation, particularly if the product eliminates tablet crushing or pharmacy compounding.
Key Takeaways
- Sucralfate is an established, off-patent drug with limited molecule-level exclusivity.
- Oral suspension is the strongest formulation opportunity.
- The highest-value excipient work concerns redispersibility, dose uniformity, palatability, preservative performance and syringe compatibility.
- Tablet development is technically simpler but exposed to severe generic price competition.
- A pediatric, veterinary or unit-dose presentation can create commercial differentiation.
- The core patent estate is weak; secondary formulation and process patents would provide narrower protection.
- Biosimilar risk does not apply because sucralfate is not a biologic.
- Supply reliability may provide more commercial value than broad patent protection.
- FDA Orange Book, Drugs@FDA and the Inactive Ingredient Database should anchor regulatory and formulation diligence.[1-3]
FAQs
Can sucralfate be formulated as a sugar-free suspension?
Yes. Sugar-free systems can use polyols or high-intensity sweeteners, but the sponsor must evaluate viscosity, gastrointestinal tolerability, preservative effectiveness, taste and container compatibility.
Is sucralfate suitable for an oral powder sachet?
It can be considered, but the product would need to demonstrate uniform dose delivery, rapid dispersion in the specified vehicle and acceptable stability under moisture exposure. Sachet packaging may be more practical for single-dose administration than for chronic multidose use.
Do sucralfate excipients affect drug interactions?
They can. Sucralfate’s local binding and barrier properties can reduce absorption of some co-administered medicines. Excipients that alter wetting, viscosity or dispersion may affect the timing and consistency of that interaction profile.
Can a company obtain new patents on a sucralfate suspension?
Yes, a company may seek patents on a novel composition, manufacturing process, particle-size distribution, delivery system or stability profile. Patentability and enforceability depend on novelty, non-obviousness, written description and claim scope.
Is an authorized generic sucralfate product commercially attractive?
It can be attractive when paired with dependable supply, an established reference formulation and a targeted channel strategy. The opportunity is stronger for suspension, institutional and veterinary products than for an undifferentiated tablet.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/
